

Blue Cross Blue Shield of Massachusetts is an Independent Licenses of the Blue Cross and Blue Shield Association

## Medical Policy Noncontact Ultrasound Treatment for Wounds

## **Table of Contents**

- Policy: Commercial
- Authorization Information
- Description
- Information Pertaining to All Policies
- Policy History
- References
- Policy Number: 657

**Coding Information** 

BCBSA Reference Number: 2.01.79 (For Plan internal use only) NCD/LCD: N/A

## **Related Policies**

- Electrostimulation and Electromagnetic Therapy for Treating Wounds, #655
- Negative Pressure Wound Therapy in the Outpatient Setting, #543
- Noncontact Radiant Heat Bandage for the Treatment of Wounds, #656

## Policy

# Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

Noncontact ultrasound treatment for wounds is considered **INVESTIGATIONAL**.

## **Prior Authorization Information**

#### Inpatient

 For services described in this policy, precertification/preauthorization <u>IS REQUIRED</u> for all products if the procedure is performed <u>inpatient</u>.

Outpatient

• For services described in this policy, see below for products where prior authorization <u>might be</u> <u>required</u> if the procedure is performed <u>outpatient</u>.

	Outpatient
Commercial Managed Care (HMO and POS)	This is <b>not</b> a covered service.
Commercial PPO and Indemnity	This is <b>not</b> a covered service.
Medicare HMO Blue <sup>sM</sup>	This is <b>not</b> a covered service.
Medicare PPO Blue <sup>SM</sup>	This is <b>not</b> a covered service.

## **CPT Codes / HCPCS Codes / ICD Codes**

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

## **CPT Codes**

CPT codes:	Code Description
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day

## Description

Ultrasound (US) delivers mechanical vibration above the upper threshold of human hearing (>20 kHz). US in the megahertz range (1-3 MHz) has been used to treat musculoskeletal disorders, often by physical therapists. Although the exact mechanism underlying its clinical effects is not known, therapeutic US has been shown to have a variety of effects at a cellular level, including angiogenesis, leukocyte adhesion, growth factor, collagen production, and increases in macrophage responsiveness, fibrinolysis, and nitric oxide levels. The therapeutic effects of US energy in the kilohertz range have also been examined. Although the precise effects are not known, the low-frequency US in this range may improve wound healing via the production, vibration, and movement of micron-sized bubbles in the coupling medium and tissue.

The mechanical energy from the US is typically transmitted to the tissue through a coupling gel. Several high-intensity US devices with contact probes are currently available for wound débridement. Low-intensity US devices have been developed that do not require coupling gel or other direct contact. The MIST Therapy System delivers a saline mist to the wound with low-frequency US (40 KHz). A second device, the Qoustic Wound Therapy System, also uses sterile saline to deliver US energy (35 KHz) for wound débridement and irrigation.

US is intended as an adjunct to standard wound care. Therefore, the evidence is needed that demonstrates US plus standard wound care provides superior wound closure outcomes compared with standard wound care alone.

The primary endpoints of interest for trials of wound closure are as follows, consistent with 2006 guidance from the U.S. Food and Drug Administration (FDA) for the industry in developing products for the treatment of chronic cutaneous ulcer and burn wounds<sup>1</sup>.:

- Incidence of complete wound closure.
- Time to complete wound closure (reflecting accelerated wound closure).
- Incidence of complete wound closure following surgical wound closure.
- Pain control.

## **Summary**

Low-frequency ultrasound in the kilohertz range may improve wound healing. Several noncontact low-frequency ultrasound (NLFU) devices have received regulatory approval for wound treatment.

For individuals who have any wound type (acute or nonhealing) who receive noncontact low-frequency ultrasound therapy (NLFU) plus standard wound care, the evidence includes randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms, change in disease status, morbid events, quality of life, and treatment-related morbidity. The single, double-blinded, sham-controlled randomized trial, which included patients with nonhealing diabetic foot ulcers, had substantial methodologic flaws (eg, high dropout rate, baseline differences between groups) that limit the validity of the findings. In the remaining studies comprising the evidence base, all but 1 RCT comparing NLFU with standard wound care reported improved (statistically significant) results on the primary outcome with NLFU. However, these studies also had several methodologic limitations. Complete healing is the most clinically relevant outcome. None of the RCTs evaluating venous leg ulcers reported complete healing as

its primary outcome measure, and none had blinded outcome assessment. Only 1 RCT, which addressed split-thickness graft donor sites, reported on the proportion of patients with complete healing and had blinded outcome assessment. Another limitation of the body of evidence is that some standard of care interventions involved fewer visits than the NLFU intervention, and the differences in intensity of care resulting from this differential in face-to-face contact could partially explain the difference in findings between intervention and control groups. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Date	Action
3/2025	Annual policy review. References updated. Policy statements unchanged.
3/2024	Annual policy review. Description, summary, and references updated. Policy
	statements unchanged.
3/2023	Annual policy review. References updated. Policy statements unchanged.
1/2023	Annual policy review. PA information section clarified to include Medicare.
2/2022	Annual policy review. Description, summary, and references updated. Policy
	statements unchanged.
3/2021	Annual policy review. Description, summary, and references updated. Policy
	statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for
	local coverage determination and national coverage determination reference.
3/2020	Annual policy review. Description, summary, and references updated. Policy
	statements unchanged.
3/2019	Annual policy review. Description, summary, and references updated. Policy
	statements unchanged.
2/2018	Annual policy review. New references added.
2/2017	Annual policy review. New references added.
12/2016	Annual policy review. New references added.
3/2016	Annual policy review. New references added.
12/2014	Annual policy review. New references added.
2/2014	Annual policy review. New references added.
1/2014	Updated to add new CPT code 97610 and remove deleted code 0183T.
11/2011-	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No
4/2012	changes to policy statements.
12/2011	Annual policy review. Changes to policy statements.
11/2011	Reviewed - Medical Policy Group - Plastic Surgery and Dermatology. No changes to
	policy statements.
4/2011	Reviewed - Medical Policy Group - Cardiology and Pulmonology. No changes to policy
	statements.
12/2010	Reviewed - Medical Policy Group - Plastic Surgery and Dermatology. No changes to
0/0040	policy statements.
3/2010	Reviewed - Medical Policy Group - Allergy and ENT/Otolaryngology. No changes to
40/0000	policy statements.
12/2009	Reviewed - Medical Policy Group - Plastic Surgery and Dermatology. No changes to
0/0000	policy statements.
9/2009	Annual policy review. No changes to policy statements.
6/2009	Annual policy review. No changes to policy statements.
4/2009	Annual policy review. No changes to policy statements.
3/2009	Reviewed - Medical Policy Group - Allergy and ENT/Otolaryngology.
1/2000	Appual policy roviow. No changes to policy statements
1/2009	Annual policy review. No changes to policy statements.
12/2000	neliev statemente

Annual policy review. No changes to policy statements.

#### **Policy History**

10/2008

7/2008	Annual policy review. Changes to policy statements.
5/2008	Annual policy review. Changes to policy statements.
3/2008	Reviewed - Medical Policy Group - Allergy and ENT/Otolaryngology. No changes to
	policy statements.
2/2008	Annual policy review. Changes to policy statements.
8/2007	Annual policy review. No changes to policy statements.
3/2007	Annual policy review. No changes to policy statements.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information: <u>Medical Policy Terms of Use</u> <u>Managed Care Guidelines</u> <u>Indemnity/PPO Guidelines</u> <u>Clinical Exception Process</u> <u>Medical Technology Assessment Guidelines</u>

## References

- 1. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for Industry: Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment. Rockville, MD: Food and Drug Administration; 2006 June.
- 2. Food and Drug Administration. MIST[TM] Therapy System: 510(k) Premarket Notification: K050129. https://www.accessdata.fda.gov/cdrh\_docs/pdf5/K050129.pdf. Accessed December 24, 2024.
- Food and Drug Administration. 510(k) Summary: 510(k) -AR1000 Series K131096, Arobella Medical, LLC. 2014; https://www.accessdata.fda.gov/cdrh\_docs/pdf13/K131096.pdf. Accessed December 23, 2024.
- 4. Tricco AC, Antony J, Vafaei A, et al. Seeking effective interventions to treat complex wounds: an overview of systematic reviews. BMC Med. Apr 22 2015; 13: 89. PMID 25899006
- 5. Voigt J, Wendelken M, Driver V, et al. Low-frequency ultrasound (20-40 kHz) as an adjunctive therapy for chronic wound healing: a systematic review of the literature and meta-analysis of eight randomized controlled trials. Int J Low Extrem Wounds. Dec 2011; 10(4): 190-9. PMID 22184750
- Ennis WJ, Foremann P, Mozen N, et al. Ultrasound therapy for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled, multicenter study. Ostomy Wound Manage. Aug 2005; 51(8): 24-39. PMID 16234574
- 7. Peschen M, Weichenthal M, Schöpf E, et al. Low-frequency ultrasound treatment of chronic venous leg ulcers in an outpatient therapy. Acta Derm Venereol. Jul 1997; 77(4): 311-4. PMID 9228227
- 8. Chang YR, Perry J, Cross K. Low-Frequency Ultrasound Debridement in Chronic Wound Healing: A Systematic Review of Current Evidence. Plast Surg (Oakv). Feb 2017; 25(1): 21-26. PMID 29026808
- Kavros SJ, Miller JL, Hanna SW. Treatment of ischemic wounds with noncontact, low-frequency ultrasound: the Mayo clinic experience, 2004-2006. Adv Skin Wound Care. Apr 2007; 20(4): 221-6. PMID 17415030
- 10. Beheshti A, Shafigh Y, Parsa H, et al. Comparison of high-frequency and MIST ultrasound therapy for the healing of venous leg ulcers. Adv Clin Exp Med. 2014; 23(6): 969-75. PMID 25618125
- Olyaie M, Rad FS, Elahifar MA, et al. High-frequency and noncontact low-frequency ultrasound therapy for venous leg ulcer treatment: a randomized, controlled study. Ostomy Wound Manage. Aug 2013; 59(8): 14-20. PMID 23934374
- 12. White J, Ivins N, Wilkes A, et al. Non-contact low-frequency ultrasound therapy compared with UK standard of care for venous leg ulcers: a single-centre, assessor-blinded, randomised controlled trial. Int Wound J. Oct 2016; 13(5): 833-42. PMID 25619411
- 13. Gibbons GW, Orgill DP, Serena TE, et al. A prospective, randomized, controlled trial comparing the effects of noncontact, low-frequency ultrasound to standard care in healing venous leg ulcers. Ostomy Wound Manage. Jan 2015; 61(1): 16-29. PMID 25581604
- 14. Prather JL, Tummel EK, Patel AB, et al. Prospective Randomized Controlled Trial Comparing the Effects of Noncontact Low-Frequency Ultrasound with Standard Care in Healing Split-Thickness Donor Sites. J Am Coll Surg. Aug 2015; 221(2): 309-18. PMID 25868409

- 15. Gottrup F, Apelqvist J, Price P. Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management. J Wound Care. Jun 2010; 19(6): 237-68. PMID 20551864
- Association for the Advancement of Wound Care (AAWC). Guideline of Pressure Ulcer Guidelines. 2010; https://s3.amazonaws.com/aawcnew/memberclicks/AAWCPressureUlcerGuidelineofGuidelinesAug11.pdf. Accessed December 23, 2024.
- Association for the Advancement of Wound Care (AAWC). International Consolidated Venous Ulcer Guideline (ICVUG) 2015 (Update of AAWC Venous Ulcer Guideline, 2005 and 2010). 2015; https://aawconline.memberclicks.net/assets/appendix%20c%20guideline%20icvugtextformatrecommendations-final%20v42%20changessaved18aug17.pdf. Accessed December 24, 2024.
- 18. National Institute for Health and Care Excellence. Medical technologies guidance (MTG5): The MIST Therapy system for the promotion of wound healing. July 25, 2011; https://www.nice.org.uk/guidance/mtg5/chapter/1-Recommendations. Accessed December 23, 2024.
- O'Donnell TF, Passman MA, Marston WA, et al. Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery 
   <sup>®</sup> and the American Venous Forum. J Vasc Surg. Aug 2014; 60(2 Suppl): 3S-59S. PMID 24974070
- Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg. Feb 2016; 63(2 Suppl): 3S-21S. PMID 26804367